Drug intelligence / Profile preview

DW-0920

Development stage: Unknown
Administration: Oral

Overview

DW-0920 is an investigational drug that has undergone Phase 1 clinical evaluation to assess its safety and pharmacokinetics in healthy male volunteers under fasting conditions. The specific mechanism of action, molecular target, modality, and therapeutic indication for DW-0920 have not been disclosed in the available public sources. The study was designed to compare DW-0919 and DW-0920, but no further details about the compound’s class or intended use are provided[2].

Beyond the preview

Go deeper on DW-0920.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW-0920.

Explore the full profile